Introduction:
Calluna Pharma Inc, a clinical-stage biotech company, has raised €75m in a Series A financing round led by Forbion. The company resulted from the merger of Dutch Oxitope Pharma and Norwegian Arxx Therapeutics. Calluna Pharma aims to develop therapies for inflammatory and fibrotic diseases by targeting innate immunity.
- Calluna Pharma Inc, a clinical-stage biotech company, has raised €75m in a Series A financing round led by Forbion.
- The company resulted from the merger of Dutch Oxitope Pharma and Norwegian Arxx Therapeutics.
- Calluna Pharma aims to develop therapies for inflammatory and fibrotic diseases by targeting innate immunity.
- The company’s pipeline includes four selective antibodies that target immunological diseases.
- The lead program, CAL101, is in Phase 1 for fibrosis and inflammation indications, with Phase Iia trials scheduled to start in 2026.
Conclusion:
Calluna Pharma Inc has raised €75m in a Series A financing round to develop therapies for inflammatory and fibrotic diseases. The company’s merger and focus on targeting innate immunity positions it well in the field of immunological diseases. With its pipeline of selective antibodies and lead program in Phase 1, Calluna Pharma is poised to make significant advancements in the treatment of these diseases.
